222. 一次性ネフローゼ症候群
[臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04424862
(ClinicalTrials.gov)
June 20207/6/2020Multitarget Therapy for Idiopathic Membranous NephropathyMultitarget Therapy for Idiopathic Membranous NephropathyEfficacyDrug: Prednisone, ciclosporin and mycophenolate mofetil;Drug: Ponticelli RegimenBeijing Friendship HospitalNULLNot yet recruiting18 Years70 YearsAll78Phase 4China
2NCT03170323
(ClinicalTrials.gov)
July 1, 201826/5/2017Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous NephropathyA Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous NephropathyIdiopathic Membranous NephropathyDrug: Mycophenolate Mofetil;Drug: CyclosporinsGuangdong Provincial People's HospitalNULLRecruiting18 YearsN/AAll128Phase 4China
3NCT03180723
(ClinicalTrials.gov)
July 1, 20173/6/2017Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisEffect of Rituximab in Treatment of Primary Membranoproliferative GlomerulonephritisMembranoproliferative GlomerulonephritisDrug: Rituximab;Drug: CyclosporinAssiut UniversityNULLNot yet recruiting18 YearsN/AAll30Phase 3NULL
4NCT02173106
(ClinicalTrials.gov)
June 201423/6/2014A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous NephropathyOpportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical TrialIdiopathic Membranous Nephropathy;Proteinuria;Spontaneous Remission;Steroid Nephropathy;Cyclosporin OverdoseDrug: steroid & CyclosporinSun Yat-sen UniversityNULLRecruiting14 Years75 YearsBoth180Phase 2China
5NCT01180036
(ClinicalTrials.gov)
November 201110/8/2010MEmbranous Nephropathy Trial Of RituximabA Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)Idiopathic Membranous NephropathyDrug: Rituximab;Drug: CyclosporineMayo ClinicColumbia University;University of British Columbia;Ohio State University;Stanford University;University of Washington;University of Michigan;University of Alabama at Birmingham;Case Western Reserve University;The Cleveland Clinic;University of Kansas Medical Center;University of Manchester;University Health Network, Toronto;University of Toronto;CHU de Quebec-Universite Laval;Washington University School of Medicine;Florida International University;University of Mississippi Medical Center;NYU Langone Health;Medical College of Wisconsin;University of Arizona;Sunnybrook Health Sciences Centre;Applied Health Research Centre;Fulk Family FoundationCompleted18 Years80 YearsAll130Phase 2/Phase 3United States;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01282073
(ClinicalTrials.gov)
March 201119/1/2011Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous NephropathyA Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous NephropathyGlomerulonephritis, MembranousDrug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin, low dose steroidKyungpook National UniversityHanmi Pharmaceutical Company LimitedRecruiting18 YearsN/ABoth62Phase 3Korea, Republic of
7NCT00977977
(ClinicalTrials.gov)
December 2, 201015/9/2009Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRituximab Plus Cyclosporine in Idiopathic Membranous NephropathyNephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous GlomerulonephritisDrug: Rituximab Infusion;Drug: Oral CyclosporineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLRecruiting18 Years100 YearsAll30Phase 2United States
8JPRN-UMIN000000963
2007/10/0101/01/2010Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome Minimal change nephrotic syndromeadministration of cyclosporineYoshihiko SaitoNULLComplete: follow-up complete20years-old75years-oldMale and Female30Not applicableJapan
9JPRN-UMIN000001099
2007/10/0131/03/2008Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndrome idiopathic membranous nephropathy associated with nephrotic syndromeSteroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.)
Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted.
Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of MedicineNULL16years-oldNot applicableMale and Female50Phase 4Japan
10JPRN-UMIN000000621
2007/03/0128/02/2007Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission Minimal change nephrotic syndromePrednisolone (+), combination therapy (-)
Prednisolone (+), combination therapy (+)
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, JapanNULLComplete: follow-up complete16years-oldNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11JPRN-UMIN000004653
2005/01/0102/12/2010The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS minimal change nephrotic syndromecyclosporine A 2-3mg/kg/dayYokohama city university graduate school of medicineNULLComplete: follow-up continuing16years-oldNot applicableMale and Female20Not applicableJapan
12NCT00135811
(ClinicalTrials.gov)
November 200424/8/2005Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)Focal Segmental Glomerulosclerosis Clinical TrialGlomerulosclerosis, FocalDrug: Cyclosporin;Drug: MMF and DexamethasoneNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)The Cleveland ClinicCompleted2 Years40 YearsBoth207Phase 3United States
13JPRN-C000000369
2004/04/0127/03/2006Multicenter study for combined therapy of prednisolone and cyclosporin in refractory nephrotic syndrome membranouos nephropathy and focal segmental glomerulosclerosis with primary steroid resistant nephrotic syndromeCyA-MEPC once a day per os administration at 3mg/kgBW for 48 weeks
CyA-MEPC twice a day per os administration at total 3mg/kgBW for 48 weeks
Project team for treatment of refractory nephrotic syndromeThe Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, JapanComplete: follow-up complete16years-old75years-oldMale and Female300Not selectedJapan